They then analyzed where the HCV had mutated so as to become resistant to both these compounds, and this analysis together with the structure of the two compounds revealed that NS5A was their mutual target.
What am I missing... ? I can see how this would isolate a part of the hcv genome that evolves resistance to multiple drugs - but I don't see how this leads ipso facto to a drug that targets the part of the genome that can't change (and thus would be a good target for a drug).
PS I read the abstract you provided and it seems to imply that they found a drug that has as its target a part of NS5A that doesn't change - but it doesn't really describe how they isolated it. Perhaps I'll have to splurge for the article - but since it is a little outside of my mainstream interest I am hoping I can be cheap -g-.
Market Data 
Markets 
AI
